Treatment of neuropathic urinary and faecal incontinence.

Eur J Pediatr Surg

Department of Paediatric Urology, The Children's Memorial Health Institute, Warsaw, Poland.

Published: October 2002

The author presents 14 children after meningomyelocoele repair with faecal and urinary incontinence, aged from 6 to 17 years who have undergone the MACE procedure. MACE with synchronous Mitrofanoff continent stoma creation was performed in one child with severe stenosis of the urethra. MACE with simultaneous bladder augmentation was used in 10 patients. 5 of them underwent colocystoplasty, 3 had ileocystoplasty and 2 ureterocystoplasty. Of these 10 children, three have additionally undergone the Mitrofanoff procedure. Patients' follow-up ranged from six months to two years. Three children had trouble with the MACE stoma because of its stenosis. One of them required revision of the stoma. All patients became clean and dry, and this operation improved not only their quality of life, but also their independence.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2002-35954DOI Listing

Publication Analysis

Top Keywords

treatment neuropathic
4
neuropathic urinary
4
urinary faecal
4
faecal incontinence
4
incontinence author
4
author presents
4
presents children
4
children meningomyelocoele
4
meningomyelocoele repair
4
repair faecal
4

Similar Publications

Background: Lowering barometric pressure (LP) can exacerbate neuropathic pain. However, animal studies in this field are limited to a few conditions. Furthermore, although sympathetic involvement has been reported as a possible mechanism, whether the sympathetic nervous system is involved in the hypothalamic-pituitary-adrenal (HPA) axis remains unknown.

View Article and Find Full Text PDF

Peripheral nerve injury (PNI)-induced neuropathic pain (NP) is a severe disease with high prevalence in clinics. Gene reprogramming and tissue remodeling in the dorsal root ganglia (DRG) and spinal cord (SC) drive the development and maintenance of neuropathic pain (NP). However, our understanding of the NP-associated spatial molecular processing landscape of SC and the non-synaptic interactions between DRG neurons and SC cells remains limited.

View Article and Find Full Text PDF

Background: Pain is a common symptom of multiple sclerosis (MS). The reliability of outcome measures for pain and the accuracy of screening tools are essential for treatment purposes.

Objectives: This study investigated the test-retest reliability of Neuropathic Pain Scale (NPS), Neuropathic Pain Symptom Inventory (NPSI), Brief Pain Inventory-Short Form (BPI-SF), Nordic Musculoskeletal Questionnaire (NMQ), Douleur Neuropathique 4 (DN4), and painDETECT, and the accuracy of DN4 and painDETECT.

View Article and Find Full Text PDF

Histamine H receptor blockade alleviates neuropathic pain through the regulation of glial cells activation.

Biomed Pharmacother

January 2025

Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Neurochemistry, 12 Smetna Str., Krakow 31-343, Poland. Electronic address:

Neuropathic pain is a disorder affecting the somatosensory nervous system. However, this condition is also characterized by significant neuroinflammation, primarily involving CNS-resident non-neuronal cells. A promising target for developing new analgesics is histamine H receptor (HR); thus, we aimed to determine the influence of a novel HR antagonist/inverse agonist, E-98 (1-(7-(4-chlorophenoxy)heptyl)-3-methylpiperidine), on pain symptoms and glia activation in model of neuropathic pain in male mice (chronic constriction injury to the sciatic nerve).

View Article and Find Full Text PDF

Intranasal Administration of the Combination of Dextro-Ketamine and Dexmedetomidine for Treatment of Diabetic Neuropathic Pain in Rats.

J Pain Res

January 2025

Programa de Pós-Graduação em Medicina (Cirurgia Geral), Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Introduction: Diabetes mellitus (DM) has become a public health problem, which is associated with high morbidity and mortality, due to the chronic complications, such as diabetic neuropathy. Current recommendations for the treatment of neuropathic pain achieve a reduction of 30% in only 30% of cases. Therefore, it is necessary to identify new therapeutic approaches to improve the quality of life of diabetic patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!